ClostraBio is dedicated to understanding and treating food allergies and other disease of the immune system. Founded in 2016 by Cathryn R. Nagler, PhD and Jeffrey A. Hubbell, PhD, ColstraBio is making strides in the discovery and development of new therapeutics that modulate the protective ability of the microbiome. ClostraBio’s team is passionate about treating diseases linked to allergic reactions like eczema, asthma, and allergic rhinitis. With assistance from the Polsky Center’s Technology Commercialization and Licensing team, the company was advised on how to define and protect its intellectual property. With this knowledge and their goals in mind, the company set its sights on the 2017 Edward L. Kaplan, ’71, New Venture Challenge (NVC) and the George Shultz Innovation Fund. John Colson, PhD, Director of Operations, along with Chicago Booth students, William Aubin, Su Fu, and Monica Vajani were awarded $40,000 and a fourth place finish at the NVC. That same week, ClostraBio was awarded up to $200,000 by the Shultz Innovation Fund advisory committee after the team’s presentation on their work that targets food allergies. The company has been featured by CBS News, BBC News, and Time Magazine among others. Go give this company a follow @ClostraBio as they look to transform the classification of allergic reactions as we know it.
Stats:
- Founded by Cathryn R. Nagler, PhD and Jeffrey A. Hubbell, PhD
- 4th place at the 2017 New Venture Challenge
- Awarded up to $200,000 at the 2017 George Shultz Innovation Fund Finals
- Headquartered in Chicago, IL
- @ClostraBio